NasdaqGS:ACADBiotechs
ACADIA Pharmaceuticals (ACAD) Stock Jumps As Valuation Gap Draws Focus
ACADIA Pharmaceuticals stock jumped 6.1% to US$28.80 after earnings, capping a strong run over the past three months. The move lines up with what the numbers signal. Q2 2026 revenue reached US$307.96 million and net income was US$31.5 million, keeping ACADIA on a solid profitability footing. Yet the real story for anyone thinking beyond this quarter is how that improving earnings base sits against a P/E of 13 and a discounted cash flow estimate of US$87.67 per share. The short term is...